基本信息
views: 5
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
It is predicted that there will be 1.2 million non-skin cancers diagnosed in North America in 2016; seventy-five percent of these (i.e., 900,000 cancer patients) will receive radiotherapy sometime during the course of their disease. Improving the efficacy of radiotherapy would significantly contribute to cancer treatment in general given its pervasiveness as an anti-neoplastic therapy. To date, advances in radiotherapy have primarily involved a variety of fractionation schemes, improved dose delivery, and improved localization. Intensity modulated radiation therapy (IMRT), which attempts to more precisely direct dose to the tumor and limit the dose to normal structures, may allow further schedule modification in the future. Because of the physical limitations of radiation dose delivery, further technical improvements are likely to provide only incremental benefits. For this reason, further increases in tumor control will require a greater understanding of the underlying tumor response to radiation. In addition to the recent advances in the technical aspects of radiation delivery, there has been considerable progress in the delineation of the molecules and processes that regulate cellular radiosensitivity and the characterization of the molecular responses to radiation.
These advances in fundamental radiobiology suggest that improvements in tumor control can be achieved through strategies that combine radiation and molecular targeting, which is the primary focus of my laboratory efforts. As an adjunct to these laboratory efforts, I have translated several of my laboratory findings into ROB clinical trials. We have recently completed a Phase II trial of the histone deacetylase inhibitor (HDACi), valproic acid (VA), in combination with Temodar and radiotherapy for patients with GBMs. This was a direct translation from studies in my laboratory showing that VA enhances the sensitivity of glioma cell lines to radiation both in vitro and in vivo (1).
Another area of translational research within my lab is the development of non-invasive surrogate biomarkers for tumor recurrence following irradiation. Current methods to evaluate patients after radiotherapy include a history and physical, laboratory studies and imaging. As none of these techniques is very sensitive to a small number of tumor cells, the development of surrogate biomarkers may allow earlier targeted adjuvant therapy only to those patients who may benefit. We are currently conducting a Phase II trial in patients with Glioblastoma multiforme (GBMs) comparing the patient's urinary VEGF and MMP-2 levels, as early biomarkers of disease progression following the completion of radiotherapy, to the clinical parameters that comprise the recursive partition analysis (RPA) of the Radiation Therapy Oncology Group (RTOG), which are currently used to stratify patients and predict progression free survival and overall survival.
Research Interests
Papers共 538 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of neuro-oncologyno. 2 (2024): 349-359
Shreya Chappidi, Hawon Lee,Sarisha Jagasia, Casey Syal, George Zaki, Dylan Junkin, Nathan Golightly, Patrick Chitwood,Kevin Camphausen,Andra Krauze
Frontiers in oncology (2024): 1348105-1348105
Mason J. Belue,Stephanie A. Harmon, Shreya Chappidi,Ying Zhuge,Erdal Tasci,Sarisha Jagasia, Thomas Joyce,Kevin Camphausen,Baris Turkbey,Andra V. Krauze
Scientific reportsno. 1 (2024): 12363-12363
Erdal Tasci,Yajas Shah,Sarisha Jagasia,Ying Zhuge, Jason Shephard,Margaret O. Johnson,Olivier Elemento, Thomas Joyce, Shreya Chappidi,Theresa Cooley Zgela,Mary Sproull,Megan Mackey,
Current oncology (Toronto, Ont.)no. 9 (2023): 8278-8293
HEALTH PHYSICSno. 1 (2023): 24-24
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 546
#Citation: 18519
H-Index: 71
G-Index: 124
Sociability: 8
Diversity: 3
Activity: 111
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn